MediVector, Inc. is a profitable, privately held company founded in January 1998, which develops drug candidate specific, customized clinical process management systems and improves the efficiency of clinical development. MediVector has demonstrated in the pharma and biotech setting that its approach results in faster, less expensive and "smarter" drug development as compared with the best drug development practices.

Rationale for MediVector's Approach

Time is critical in drug development. Many industries have cumbersome, inefficient processes that affect the bottom line. However, in the pharmaceutical industry inefficiencies can and do impact lives. Despite the successes of research and development in the continued advancement of medical care, patience on Wall Street has grown thin and investors are no longer willing to wait 10 years or more before a drug is brought to market. Indeed, pressures on the pharmaceutical industry have never been greater. Today investors flee to "safer" environments where they believe they can more easily and quickly see a return on their investment.

MediVector understands that to be successful, pharma companies must rethink their organizational philosophies, structures and processes. They must break out of the traditional hierarchical, vertically functioning organizations and begin to think and function as an interdependent, results-oriented network of alliances.

MediVector works with its clients to decrease both the time and costs of bringing drugs to market. Rather than sequential processes typical of current drug development practices, MediVector has developed concurrent processes that rely upon a continuous cycle of learning and confirming. Distinctive strategies employed include parallel processing and integration of steps in the development process and the usage of cross-functional teams, rather than traditional functional project management teams.